美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Endovia Health Sciences Inc

0.2492

+0.00522.13%

盤後：0.24940.0002+0.08%19:35 EDT

成交量：24.94萬

成交額：6.23萬

市值：157.00萬

市盈率：-0.02

高：0.2638

開：0.2489

低：0.2400

收：0.2440

52周最高：13.40

52周最低：0.2325

股本：630.00萬

流通股本：629.95萬

量比：1.47

換手率：3.96%

股息：- -

股息率：- -

每股收益(TTM):-13.6011

每股收益(LYR):-70.9984

淨資產收益率：--

總資產收益率：-77.70%

市淨率：-0.10

市盈率(LYR):0.00

資料載入中...

總覽公司新聞公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞

Endovia Health Sciences歡迎聯邦大麻素政策轉向，推進Cannepil FDA申報，並拓展研發管線

Endovia Health Sciences：即將提交Cannepil FDA申報材料並申請會前會議——SEC文件披露

Endovia Health Sciences：首推Cannepil，聚焦伴侶動物癌症疼痛，從犬類腫瘤學起步

Endovia Health Sciences：擬依據FDA「次要用途/次要物種」認定及附條件批准途徑推進研發

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/EDVA"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"EDVA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EDVA\",,,,,undefined,":{"symbol":"EDVA","market":"US","secType":"STK","nameCN":"Endovia Health Sciences Inc","latestPrice":0.2492,"timestamp":1789156800000,"preClose":0.244,"halted":0,"volume":249438,"hourTrading":{"tag":"盘后","latestPrice":0.2494,"preClose":0.2492,"latestTime":"19:35 EDT","volume":2215,"amount":555.8122,"timestamp":1789169702004,"change":0.0002,"changeRate":0.000803,"amplitude":0.003612},"delay":0,"changeRate":0.02131147540983611,"floatShares":6299531,"shares":6300000,"eps":-13.601116,"marketStatus":"休市中","change":0.0052,"latestTime":"09-11 16:00:00 EDT","open":0.24885,"high":0.263799,"low":0.24,"amount":62257.07576844,"amplitude":0.097537,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-13.601116,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"exchange":"AMEX","adjPreClose":0.244,"preHourTrading":{"tag":"盘前","latestPrice":0.2489,"preClose":0.244,"latestTime":"09:17 EDT","volume":5802,"amount":1431.31371432,"timestamp":1789132634679,"change":0.0049,"changeRate":0.020082,"amplitude":0.103689},"postHourTrading":{"tag":"盘后","latestPrice":0.2494,"preClose":0.2492,"latestTime":"19:35 EDT","volume":2215,"amount":555.8122,"timestamp":1789169702004,"change":0.0002,"changeRate":0.000803,"amplitude":0.003612},"volumeRatio":1.4740438779640679},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EDVA\",,,,,undefined,":{"symbol":"EDVA","floatShares":6299531,"roa":"-77.70%","roe":"--","lyrEps":-70.998368,"volumeRatio":1.4740438779640679,"shares":6300000,"dividePrice":0,"high":0.263799,"amplitude":0.097537,"preClose":0.244,"low":0.24,"week52Low":0.2325,"pbRate":"-0.10","psRate":"48.92","week52High":13.3996,"institutionHeld":0,"latestPrice":0.2492,"eps":-13.601116,"divideRate":0,"volume":249438,"delay":0,"ttmEps":-13.601116,"open":0.24885,"prevYearClose":2.7616,"prevWeekClose":0.264,"prevMonthClose":0.302,"prevQuarterClose":0.62,"fiveDayClose":0.2685,"twentyDayClose":0.3943,"sixtyDayClose":0.792},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EDVA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-19","symbol":"EDVA","fiscalQuarterEnding":"2026/06","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1787112000000,"reportTimeType":"post","actualEps":-0.77}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EDVA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EDVA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EDVA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EDVA","date":"2026-09-11","current":-0.018322,"percent":0.916667,"low":-0.155169,"twenty":-0.128751,"median":-0.109605,"eighty":-0.095565,"high":-0.090534,"avg":-0.111888,"sd":0.019546,"marketCap":1564655},"quantilePoints":[{"date":"2026-08-28","current":-0.118733,"twenty":-0.145082,"median":-0.136894,"eighty":-0.128751,"marketCap":2052006},{"date":"2026-09-04","current":-0.099624,"twenty":-0.136601,"median":-0.114948,"eighty":-0.105613,"marketCap":1721761},{"date":"2026-09-11","current":-0.090534,"twenty":-0.128751,"median":-0.109605,"eighty":-0.095565,"marketCap":1564655}],"updateTime":1789316883312},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EDVA\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1170636079","title":"Endovia Health Sciences歡迎聯邦大麻素政策轉向，推進Cannepil FDA申報，並拓展研發管線","url":"https://stock-news.laohu8.com/highlight/detail?id=1170636079","media":"美股速递","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170636079?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 04:10","pubTimestamp":1788207011,"startTime":"0","endTime":"0","summary":"Endovia Health Sciences对联邦层面大麻素政策的重大转变表示欢迎。该公司在提交给美国证券交易委员会的文件中披露，其正全力推进Cannepil的FDA申报工作，并同步拓展研发管线。Endovia Health Sciences积极响应该变化，并将其视为加速核心产品开发的关键契机。与此同时，Endovia Health Sciences也并未止步于单一产品。此次政策变动，加之公司自身在研发和申报上的双重发力，共同勾勒出Endovia Health Sciences在动态监管环境下主动求变、深化发展的清晰轮廓。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4169","EDVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135316178","title":"Endovia Health Sciences：即將提交Cannepil FDA申報材料並申請會前會議——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1135316178","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135316178?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 04:10","pubTimestamp":1788207010,"startTime":"0","endTime":"0","summary":"Endovia Health Sciences（简称EDVA）于本周向美国证券交易委员会（SEC）提交的文件中透露，计划在未来一周内递交其Cannepil产品的FDA申请，并同时请求召开一次预提交会议（Pre-Submission Conference）。这一动态标志着该公司在推进其关键候选药物监管审批道路上迈出了重要一步。据悉，预提交会议旨在通过与FDA的早期沟通，明确申报路径中的潜在问题，从而优化后续审批流程的效率和成功率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDVA","BK4169"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187898799","title":"Endovia Health Sciences：首推Cannepil，聚焦伴侶動物癌症疼痛，從犬類腫瘤學起步","url":"https://stock-news.laohu8.com/highlight/detail?id=1187898799","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187898799?lang=zh_tw&edition=fundamental","pubTime":"2026-08-25 20:32","pubTimestamp":1787661162,"startTime":"0","endTime":"0","summary":"Endovia Health Sciences公司宣布，其初期战略将锁定Cannepil这一产品，专门用于缓解伴侣动物因癌症引发的疼痛。而这一计划的起点，正是犬类肿瘤治疗领域。伴侣动物的癌症疼痛管理，长期面临方案匮乏的困境。Endovia此番入局，显然意在填补这一空白。Cannepil作为核心产品，其定位清晰：直击癌症相关疼痛，而非泛泛的镇痛市场。目前，Endovia尚未透露Cannepil的具体上市时间表。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107920718","title":"Endovia Health Sciences：擬依據FDA「次要用途/次要物種」認定及附條件批准途徑推進研發","url":"https://stock-news.laohu8.com/highlight/detail?id=1107920718","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107920718?lang=zh_tw&edition=fundamental","pubTime":"2026-08-25 20:32","pubTimestamp":1787661162,"startTime":"0","endTime":"0","summary":"Endovia Health Sciences宣布，其有意在美国食品药品监督管理局的“次要用途/次要物种”认定框架下，推动相关产品的研发工作，并计划采用该机构设定的附条件批准路径。Endovia Health Sciences尚未披露具体的候选产品细节，但明确表达了其致力于在这一特殊监管框架内，探索并推进创新疗法的坚定意向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDVA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/EDVA\",params:#limit:6,delay:false,,,undefined,":[]}}